CLINICAL TRIALS

Fenofibrate


Study Title:  A Phase IIA, Randomized, Double-blind, Placebo-controlled study of the safety and efficacy of fenofibrate as a treatment for Huntington’s Disease

Purpose: To study the safety and efficacy of fenofibrate, an FDA approved drug to treat cholesterol, as a treatment for Huntington’s disease (HD)

Study drug: 145mg of fenofibrate vs. placebo (75% chance of active drug; 25% chance of placebo)

Duration of study: 6 months with 8 in-clinic visits

Inclusion criteria:

  • Age 18 or older
  • Clinical findings of Huntington’s disease (HD) and a confirmed family history of HD
  • Clinical findings of HD and a CAG repeat of ≥ 36​
  • Good overall health status
  • Must be able to take oral medication

Exclusion criteria:

  • Diagnosis of another major neurological disease (e.g., multiple sclerosis, Parkinson’s disease, cortical stroke)
  • History of gallstones
  • History of known sensitivity to any fibrate medication
  • Exposure to another investigational medicine within 30 days prior to baseline visit
  • Current or recent (within 3 months of screening visit) use of dopamine blocking agents such as: tetrabenazine, antipsychotics, metoclopramide, prochlorperazine, or HAART
  • Current use of Warfarin (Coumadin)
  • Current use of statins (e.g., simvastatin, atorvastatin, etc.)
  • Are pregnant or lactating


Please note: the above may not be a complete list of inclusion
and/or exclusion criteria

For more information, please contact the

UC Irvine Neurology Clinical Trials Unit at

one of the following:


(949) 824 – 3485
(949) 824 – 7524


Everlyne Gomez: everlyng@uci.edu

Enroll-HD


Study Title:  A Prospective Registry Study in a Global Huntington’s Disease Cohort (A CHDI Foundation Project)

Purpose: To collect clinical information about subjects and their health. In addition, biological samples (DNA and blood) will be collected to learn more about HD and try to find new treatments for the disease.

Study drug: No study medication or device 

Duration of study: No study medication or device 

Inclusion criteria:

  • Age 18 or older
  • Carriers: individuals with the HD gene expansion mutation
  • Genotype Unknown: first or second degree relatives who have not undergone HD testing, and have an unknown carrier type
  • Family/Community Controls: individuals without HD or any family history of HD

Exclusion criteria:

  • Have choreic movement disorders in the context of a negative test for the HD mutation
  • For controls: history of concurrent major central nervous system (e.g., stroke, Parkinson’s disease, etc.)


Please note: the above may not be a complete list of inclusion and/or exclusion criteria

HUNTINGTON'S DISEASE CLINICAL TRIALS


A LISTING OF HUNTINGTON'S DISEASE MEDICAL RESEARCH TRIALS ACTIVELY RECRUITING PATIENT VOLUNTEERS. CLICK ON THE CLOSEST CITY TO FIND MORE DETAILED INFORMATION ON A RESEARCH STUDY IN YOUR AREA.

LINK: https://www.centerwatch.com/clinical-trials/listings/condition/82/huntingtons-disease 
LINK: http://hdtrialfinder.org/

CLINICAL TRIALS CURRENTLY RECRUITING
Department of Neurology

Community
Advocacy
Research &

Education

Pfizer clinical trials


A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-Concept Study of the Efficacy and Safety of PF-02545920 in Subjects with Huntington’s Disease

Protocol Number: A8241021


Purpose of Study: The purpose of this research study is to compare the safety,tolerability and effectiveness of two doses of PF-02545920 to placebo on improving voluntary movement and overall symptoms in subjects with Huntington’s disease. A placebo looks like the study drug but does not contain any drug. Researchers use a placebo to see if the study drug works better or is safer than not taking anything.


Eligibility:


You can participate in this study if you:


  • Are 30-65 years of age

  • Diagnosed with Huntington’s disease


Contact Name:

UCI Department, Phone Number and E-mail: Department of Neurology – Clinical Trials Unit, Katrina Samson at (949) 824-3485 or samsonk@uci.edu


Please download the full text for further details and information.


Informational Brochure



To seek information on other trials that may be available:


Contact:

Rabia Farooquee
Assistant Clinical Research Coordinator
Department of Neurology
University of California, Irvine
(949) 824-7524
rfarooqu@uci.edu


Additional Resouce:

Website: https://clinicaltrials.gov/

Visit clinicaltrials.gov and search "Huntington's Disease" to find clinical trials conducted throughout the United States. ​​